Literature DB >> 10727988

Expression of the CD30 antigen in non-lymphoid tissues and cells.

H Dürkop1, H D Foss, F Eitelbach, I Anagnostopoulos, U Latza, S Pileri, H Stein.   

Abstract

Originally, expression of the CD30 antigen was shown to be typical of the tumour cells of Hodgkin's disease (HD) and of anaplastic large cell lymphomas (ALCLs). In reactive lymphoid tissue, CD30 is expressed only in a small population of activated lymphoid blasts. Since then, several reports have been published describing CD30 expression in non-lymphoid tissues and malignancies, such as embryonal carcinomas (ECs), seminomas, cultivated macrophages, two histiocytic neoplasms, decidual cells, and mesotheliomas. As CD30 detection is important in the differential diagnosis of HD and ALCL, the expression of CD30 in different non-lymphoid tissues was re-evaluated by immunohistology and in situ hybridization. Extra-lymphoid CD30 expression was found in 48/51 cases of EC or EC components of germ cell tumours, in decidual cells of 1/10 cases, in activated mesothelium in 16/28 pleural and peritoneal effusions, and in small foci of tumour cells in 2/8 mesotheliomas. CD30 expression was not confirmed in 27 germ cell tumours of the testis without an EC component nor in cultivated macrophages and 17 histiocytic malignancies. The knowledge of these CD30 expression patterns is important for the immunohistological differential diagnosis of anaplastic tumours. The absence of CD30 expression in reactive and neoplastic macrophages does not favour the concept that HD and ALCL are derived from these cells. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10727988     DOI: 10.1002/(SICI)1096-9896(200004)190:5<613::AID-PATH559>3.0.CO;2-0

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  28 in total

1.  Expansion of human embryonic stem cells: a comparative study.

Authors:  V T'joen; H Declercq; M Cornelissen
Journal:  Cell Prolif       Date:  2011-10       Impact factor: 6.831

2.  Histone acetylation and DNA demethylation of T cells result in an anaplastic large cell lymphoma-like phenotype.

Authors:  Maria Joosten; Volkhard Seitz; Karin Zimmermann; Anke Sommerfeld; Erika Berg; Dido Lenze; Ulf Leser; Harald Stein; Michael Hummel
Journal:  Haematologica       Date:  2012-08-16       Impact factor: 9.941

3.  CD30 is a potential therapeutic target in malignant mesothelioma.

Authors:  Snehal Dabir; Adam Kresak; Michael Yang; Pingfu Fu; Gary Wildey; Afshin Dowlati
Journal:  Mol Cancer Ther       Date:  2015-01-14       Impact factor: 6.261

4.  Noninvasive Trafficking of Brentuximab Vedotin and PET Imaging of CD30 in Lung Cancer Murine Models.

Authors:  Lei Kang; Dawei Jiang; Emily B Ehlerding; Todd E Barnhart; Dalong Ni; Jonathan W Engle; Rongfu Wang; Peng Huang; Xiaojie Xu; Weibo Cai
Journal:  Mol Pharm       Date:  2018-03-20       Impact factor: 4.939

5.  Circulating CD30+CD4+ T Cells Increase Before Human Immunodeficiency Virus Rebound After Analytical Antiretroviral Treatment Interruption.

Authors:  Cecilia A Prator; Cassandra Thanh; Shreya Kumar; Tony Pan; Michael J Peluso; Ronald Bosch; Norman Jones; Jeffrey M Milush; Sonia Bakkour; Mars Stone; Michael P Busch; Steven G Deeks; Peter W Hunt; Timothy J Henrich
Journal:  J Infect Dis       Date:  2020-03-16       Impact factor: 5.226

Review 6.  Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies.

Authors:  Christopher G England; Lixin Rui; Weibo Cai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-11-14       Impact factor: 9.236

7.  CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma.

Authors:  Shruti Bhatt; Brittany M Ashlock; Yasodha Natkunam; Victoria Sujoy; Jennifer Rose Chapman; Juan Carlos Ramos; Enrique A Mesri; Izidore S Lossos
Journal:  Blood       Date:  2013-07-09       Impact factor: 22.113

8.  CD30 expression in malignant vascular tumors and its diagnostic and clinical implications: a study of 146 cases.

Authors:  Meghna Alimchandani; Zeng-Feng Wang; Markku Miettinen
Journal:  Appl Immunohistochem Mol Morphol       Date:  2014 May-Jun

Review 9.  Role of CD30 targeting in malignant lymphoma.

Authors:  Anita Kumar; Anas Younes
Journal:  Curr Treat Options Oncol       Date:  2014-06

10.  Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1.

Authors:  Meili Zhang; Zhengsheng Yao; Hiral Patel; Kayhan Garmestani; Zhuo Zhang; Vladimir S Talanov; Paul S Plascjak; Carolyn K Goldman; John E Janik; Martin W Brechbiel; Thomas A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.